FDMT

FDMT Operating Cash Flow (Statement)

-$156.07MTTM · USD

Period ending:

FDMT FY Cash from OperationsUSD
FDMT FY Cash from Operations2017-12-31: $8.24M2018-12-31: -$16.25M2019-12-31: -$36.71M2020-12-31: -$50.91M2021-12-31: -$69.13M2022-12-31: -$86.69M2023-12-31: -$75.79M2024-12-31: -$134.59M2025-12-31: -$109.08M$8.24M-$134.59M
2017-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

FDMT operating cash flow (statement) history

Net cash provided by operating activities. The available annual fiscal periods series contains 9 observations from Dec 31, 2017 to Dec 31, 2025.

4D Molecular Therapeutics Inc Operating Cash Flow (Statement) — Annual fiscal periods (USD)
Period endingOperating Cash Flow (Statement) (USD)
-109,082,000
-134,585,000
-75,792,000
-86,685,000
-69,134,000
-50,909,000
-36,711,000
-16,252,000
8,237,000

Compare operating cash flow (statement)

All FDMT financial metrics · FDMT stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.